CTxONE is in the business of translating Australia’s innovative research discoveries into new cancer drugs for patients. As well as pursuing its own oncology programs, CTxONE is a commercialisation partner of Cancer Therapeutics CRC (CTx), a collaborative partnership of leading medical research institutes, universities and biotechnology companies that was founded in 2007.
CTxONE is governed by an independent skills-based Board of Directors and led by a highly experienced Management Team. Our research and development capabilities span the full range of technologies and expertise required to discover novel small molecule cancer drugs and take them into early clinical development. The collaborative model CTxONE has adopted allows us early access to novel cancer biology from world leading experts from the likes of the Peter MacCallum Cancer Centre, the Walter and Eliza Hall Institute and Monash University.
The major focus of our drug discovery effort is epigenetics and immuno-oncology, two burgeoning areas of cancer research that promise to transform cancer patient outcomes.
CTxONE is based at the Victorian Comprehensive Cancer Centre in the heart of Melbourne’s biomedical precinct.